To the full analysis
medmix stock: growth
MEDX.SWmedmix reported $537.73M in revenue for fiscal 2025, down 7.4% on the prior year, up 5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−0.2%
per year from 2018 to 2025, per share 0%
Earnings (Annual rate)
−25.9%
per year from 2018 to 2025, per share −25.6%
Free cash flow (Annual rate)
−9%
per year from 2018 to 2025, per share −8.8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2018 | |
|---|---|---|
| Revenue | 5.0% | −0.2% |
| Revenue per share | 5.2% | 0.0% |
| Earnings | −7.8% | −25.9% |
| Earnings per share | −7.0% | −25.6% |
| Free cash flow | 34.7% | −9.0% |
| Free cash flow per share | 35.1% | −8.8% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2018 | $544.93M | $62.65M | $77.06M |
| 2019 | $504.96M | $30.25M | $63.49M |
| 2020 | $421.66M | $11.52M | $9M |
| 2021 | $548.89M | $52.81M | $66.5M |
| 2022 | $572.65M | $13.92M | $10.8M |
| 2023 | $584.06M | $360.08K | $3.84M |
| 2024 | $580.82M | −$8.88M | $45.73M |
| 2025 | $537.73M | $7.68M | $39.97M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CHF 0.8331)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 25 Sep 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.